ATE493985T1 - Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden - Google Patents

Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden

Info

Publication number
ATE493985T1
ATE493985T1 AT03736611T AT03736611T ATE493985T1 AT E493985 T1 ATE493985 T1 AT E493985T1 AT 03736611 T AT03736611 T AT 03736611T AT 03736611 T AT03736611 T AT 03736611T AT E493985 T1 ATE493985 T1 AT E493985T1
Authority
AT
Austria
Prior art keywords
treatment
ischemia
reperfusion injury
beta blocker
pyrroloquinoline quinones
Prior art date
Application number
AT03736611T
Other languages
English (en)
Inventor
Paul J Davis
Original Assignee
Clf Medical Technology Acceleration Program Inc
Paul J Davis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clf Medical Technology Acceleration Program Inc, Paul J Davis filed Critical Clf Medical Technology Acceleration Program Inc
Application granted granted Critical
Publication of ATE493985T1 publication Critical patent/ATE493985T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03736611T 2002-05-15 2003-05-14 Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden ATE493985T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/146,566 US7276514B2 (en) 2002-05-15 2002-05-15 Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
PCT/US2003/015187 WO2003097056A1 (en) 2002-05-15 2003-05-14 Pyrroloquinoline quinone for treatment of cardiac injury and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE493985T1 true ATE493985T1 (de) 2011-01-15

Family

ID=29418840

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03736611T ATE493985T1 (de) 2002-05-15 2003-05-14 Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden

Country Status (8)

Country Link
US (2) US7276514B2 (de)
EP (1) EP1558256B1 (de)
JP (1) JP2005530786A (de)
AT (1) ATE493985T1 (de)
AU (1) AU2003237851A1 (de)
CA (1) CA2497601A1 (de)
DE (1) DE60335647D1 (de)
WO (1) WO2003097056A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US7276514B2 (en) 2002-05-15 2007-10-02 Charitable Leadership Foundation - Medical Technology Acceleration Program Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
JP2007536256A (ja) * 2004-05-05 2007-12-13 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド 心臓損傷の処置のためのピロロキノリンキノン薬およびその使用方法
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US9139630B2 (en) 2006-07-11 2015-09-22 Rutgers, The State University Of New Jersey Compositions and methods for preparing recombinant MG53 and methods for optimizing same
EP2062892A4 (de) * 2006-09-08 2009-11-18 Kyowa Hakko Bio Co Ltd Mittel gegen hypertonie
KR101413005B1 (ko) * 2007-12-04 2014-07-02 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 세포막 재봉합을 조절하기 위한 조성물 및 방법
JP5672751B2 (ja) * 2010-04-07 2015-02-18 三菱瓦斯化学株式会社 ピロロキノリンキノンを含むリポソーム
US20130123340A1 (en) * 2010-05-11 2013-05-16 Peking University, Office Of Technology Transfer Compositions and methods for the treatment and prevention of cardiac ischemic injury
US8420338B2 (en) 2010-11-05 2013-04-16 University Of Medicine And Dentistry Of New Jersey Serum MG53 as a diagnostic marker for tissue injury
CN103533936B (zh) * 2011-05-17 2016-01-13 三菱瓦斯化学株式会社 含有吡咯并喹啉醌和糖的脂质体
PL2722331T3 (pl) 2011-06-16 2018-02-28 Mitsubishi Gas Chemical Company, Inc. Kryształ soli disodowej pirolochinolinochinonu oraz sposób jego wytwarzania
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US10364244B2 (en) * 2015-09-25 2019-07-30 Zhejiang Hisun Pharmaceutical Co., Ltd. Crystal form of pyrroloquinoline quinone sodium salt and preparation method and use thereof
US20190298684A1 (en) * 2018-03-27 2019-10-03 So Young Life Sciences Corporation Compositions For Reducing Negative Effects Of Alcohol Consumption
CN110870866A (zh) * 2018-09-03 2020-03-10 浙江医药股份有限公司新昌制药厂 吡咯喹啉醌在制备用于防治急性高原反应和急性高原低氧损伤的药物中的应用
IT202000025603A1 (it) * 2020-10-28 2022-04-28 Longeva Health S R L Composizione per prevenire e trattare lo scompenso e/o l’insufficienza cardiaca

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1302275C (en) * 1986-08-07 1992-06-02 Yuji Narutomi Enzyme inhibitor
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
US5091391A (en) * 1990-08-16 1992-02-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
US5145862A (en) * 1990-08-16 1992-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
CA2115442C (en) * 1991-09-09 2003-09-23 Christopher Franklin Bigge Pharmaceutical preparation containing an uricosuric agent and an excitatory amino acid antagonist
AU3222893A (en) 1991-11-25 1993-06-28 University Of Michigan, The Therapeutic composition and method for preventing reperfusion injury
US5460819A (en) 1991-12-13 1995-10-24 Children's Medical Center Corporation Method for treating PQQ-responsive heavy metal toxicity
US5616576A (en) * 1994-07-12 1997-04-01 The Children's Medical Center Corporation Controlling bone resorption with pyrroloquinoline quinone (PQQ) and related compounds
JP4777489B2 (ja) 1997-03-31 2011-09-21 ザ チルドレンズ メディカル センター コーポレーション アポトーシス性酵素を不活性化するためのニトロシル化
WO2004010924A2 (en) * 2002-04-04 2004-02-05 Children's Medical Center Corporation Pyrroloquinoline quinone drugs as a neuroprotectant and methods of use thereof
US7276514B2 (en) * 2002-05-15 2007-10-02 Charitable Leadership Foundation - Medical Technology Acceleration Program Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof

Also Published As

Publication number Publication date
DE60335647D1 (de) 2011-02-17
CA2497601A1 (en) 2003-11-27
US20080221145A1 (en) 2008-09-11
EP1558256B1 (de) 2011-01-05
AU2003237851A1 (en) 2003-12-02
EP1558256A1 (de) 2005-08-03
JP2005530786A (ja) 2005-10-13
US20030216424A1 (en) 2003-11-20
US7276514B2 (en) 2007-10-02
WO2003097056A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
ATE493985T1 (de) Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
DE602005012276D1 (de) Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
ATE299854T1 (de) Chinonverbindungen zur behandlung von krankheiten
DE60332101D1 (de) Antimikrobielle zusammensetzung
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
NO20060278L (no) Piperazinderivater og fremgangsmater for anvendelse
ZA202304093B (en) Neuregulin-4 compounds and methods of use
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
DE60203847D1 (de) Verbindungen enthaltend S-Tofisopam sowie Verwendung dieser Verbindungen zur Herstellung eines Medikamentes zur Behandlung oder Prophylaxe von Krämpfen und Anfällen
DE602006020335D1 (de) Verwendung von parp-1-hemmern
WO2007130509A3 (en) Pyrroloquinoline quinones and use thereof
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
ATE442854T1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
NO20052153L (no) Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.
SI1809270T1 (sl) 5,6,7-trihidroksiheptanojska kislina in analogi za zdravljenje očesnih bolezni in bolezni, povezanih s hiperproliferacijskimi in angiogenskimi odzivi
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft
WO2005107871A3 (en) Pyrroloquinoline quinone drugs for treatment of cardiac injury
EP1734996A4 (de) Verfahren und zusammensetzungen für die behandlung und vorbeugung von mit alpha v beta 5-integrin assoziierten krankheiten
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
ATE390144T1 (de) Behandlung von fibrosen
WO2003043565A3 (en) Methods for diagnosis and treatment of diseases associated with altered expression of nrf2
WO2006015183A3 (en) Pharmaceutical compositions for treating disorders of the skin
DE60313344D1 (de) Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen
DE10390702D2 (de) 2-Methylthiazolidin-2,4-Dicarbonsäure und deren Salze zur Behandlung von neurodegenerativen Erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties